MN Services Vermogensbeheer’s Abiomed Inc ABMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-24,868
Closed -$6.11M 424
2022
Q3
$6.11M Sell
24,868
-2,200
-8% -$594K 0.06% 318
2022
Q2
$6.7M Sell
27,068
-4,800
-15% -$1.3M 0.06% 334
2022
Q1
$10.6M Sell
31,868
-1,600
-5% -$493K 0.07% 289
2021
Q4
$12M Hold
33,468
0.07% 283
2021
Q3
$10.9M Buy
33,468
+300
+0.9% +$102K 0.07% 308
2021
Q2
$8.73M Buy
+33,168
New +$10.2M 0.07% 307
2020
Q4
$13.3M Buy
41,068
+2,700
+7% +$747K 0.09% 238
2020
Q3
$10.6M Hold
38,368
0.08% 236
2020
Q2
$9.27M Buy
38,368
+100
+0.3% +$20.1K 0.08% 254
2020
Q1
$5.55M Sell
38,268
-2,500
-6% -$415K 0.06% 252
2019
Q4
$6.96M Buy
40,768
+1,400
+4% +$260K 0.06% 285
2019
Q3
$7M Buy
39,368
+16,600
+73% +$3.59M 0.07% 276
2019
Q2
$5.93M Sell
22,768
-600
-3% -$159K 0.07% 310
2019
Q1
$6.67M Buy
23,368
+400
+2% +$133K 0.08% 275
2018
Q4
$6.53M Buy
22,968
+16,368
+248% +$5.69M 0.1% 218
2018
Q3
$2.97M Hold
6,600
0.07% 303
2018
Q2
$2.7M Buy
+6,600
New +$2.39M 0.07% 317

Other funds holding ABMD

MN Services Vermogensbeheer's ABMD Position: Q4 2022 in Review

MN Services Vermogensbeheer sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 24,868 shares — an estimated $6.11M sold.

MN Services Vermogensbeheer first reported a position in ABMD in Q2 2018 and held it in 17 quarters. The position peaked at $13.3M in Q4 2020. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • MN Services Vermogensbeheer reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • MN Services Vermogensbeheer sold 24,868 Abiomed Inc shares in Q4 2022, an estimated $6.11M.
  • MN Services Vermogensbeheer first reported a position in Abiomed Inc in Q2 2018 and held it in 17 quarters.
  • MN Services Vermogensbeheer's Abiomed Inc position peaked at $13.3M in Q4 2020.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on MN Services Vermogensbeheer's 13F filing for Q4 2022, filed 3 Feb 2023.